1. Home
  2. PRAX vs NICE Comparison

PRAX vs NICE Comparison

Compare PRAX & NICE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$320.24

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Logo NICE Ltd

NICE

NICE Ltd

HOLD

Current Price

$123.01

Market Cap

6.4B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
NICE
Founded
2015
1986
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
6.4B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
PRAX
NICE
Price
$320.24
$123.01
Analyst Decision
Strong Buy
Buy
Analyst Count
15
14
Target Price
$572.13
$156.07
AVG Volume (30 Days)
371.8K
1.1M
Earning Date
05-12-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$10.21
Revenue Next Year
$1,840.20
$9.70
P/E Ratio
N/A
$11.21
Revenue Growth
N/A
N/A
52 Week Low
$26.70
$94.65
52 Week High
$354.87
$180.61

Technical Indicators

Market Signals
Indicator
PRAX
NICE
Relative Strength Index (RSI) 50.06 62.91
Support Level $290.36 $104.02
Resistance Level $322.32 $137.38
Average True Range (ATR) 19.02 5.70
MACD -2.10 1.52
Stochastic Oscillator 46.86 95.79

Price Performance

Historical Comparison
PRAX
NICE

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About NICE NICE Ltd

Nice is an enterprise software company that serves the customer engagement and financial crime and compliance markets. Software is deployed primarily on the cloud, but also on premises. Within customer engagement, Nice's CXone is the leading CCaaS platform providing solutions such as call routing, interactive voice response, digital self-service, and workforce engagement management. Within financial crime and compliance, Nice offers risk and investigation management, fraud prevention, anti-money-laundering, and compliance solutions.

Share on Social Networks: